Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities

Go back to Boston Scientific Announces Agreement to Acquire Neovasc Advanced Biological Tissue Capabilities

Leerink Reaffirms Neovasc (NVCN) at 'Outperform' Amid Boston Scientific Deal

December 2, 2016 11:57 AM EST

Leerink affirms Neovasc Inc. (Nasdaq: NVCN) at Outperform with a price target of $10 following news of an asset sales agreement with Boston Scientific... More